EAM Investors’s Epizyme, Inc EPZM Stock Holding History

EAM Investors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-67,810	Closed	-$1.05M	–	347
2020 Q1	$1.05M	Sell	67,810 -13,423	-17%	-$288K	0.33%	141
2019 Q4	$2M	Buy	+81,233	New	+$1.21M	0.44%	77

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EAM Investors's EPZM Position: Q2 2020 in Review

EAM Investors sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 67,810 shares — an estimated $1.05M sold.

EAM Investors first reported a position in EPZM in Q4 2019 and held it in 2 quarters. The position peaked at $2M in Q4 2019. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

EAM Investors reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
EAM Investors sold 67,810 Epizyme, Inc shares in Q2 2020, an estimated $1.05M.
EAM Investors first reported a position in Epizyme, Inc in Q4 2019 and held it in 2 quarters.
EAM Investors's Epizyme, Inc position peaked at $2M in Q4 2019.
160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.